Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Moonlins
Zug, Zug, Switzerlandarchive.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MoonLake’s lead asset, sonelokimab, is a novel nanobody-based inhibitor of IL‑17A and IL‑17F. It has demonstrated promising efficacy in phase 2 trials for hidradenitis suppurativa and psoriatic arthritis. The company is preparing to launch phase 3 clinical trials in these indications. Sonelokimab’s mechanism allows it to target multiple forms of IL‑17 dimers implicated in inflammatory diseases, potentially offering advantages over traditional antibodies.[1][4][5][6]
- Therapeutic areas
- DermatologyRheumatology
- Modalities
- Nanobody therapyBiologic
- Industry
- Biotech
02
Partnerships
Merck KGaA (licensing agreement for sonelokimab) [4]Komodo Health (technology/data partnership) [5][6]
Beyond the preview
Go deeper on Moonlins.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moonlins.